Literature DB >> 26682140

Impacts of biological and procedural factors on semiquantification uptake value of liver in fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging.

Mohd Hafizi Mahmud1, Abdul Jalil Nordin1, Fathinul Fikri Ahmad Saad1, Ahmad Zaid Fattah Azman1.   

Abstract

BACKGROUND: Increased metabolic activity of fluorodeoxyglucose (FDG) in tissue is not only resulting of pathological uptake, but due to physiological uptake as well. This study aimed to determine the impacts of biological and procedural factors on FDG uptake of liver in whole body positron emission tomography/computed tomography (PET/CT) imaging.
METHODS: Whole body fluorine-18 ((18)F) FDG PET/CT scans of 51 oncology patients have been reviewed. Maximum standardized uptake value (SUVmax) of lesion-free liver was quantified in each patient. Pearson correlation was performed to determine the association between the factors of age, body mass index (BMI), blood glucose level, FDG dose and incubation period and liver SUVmax. Multivariate regression analysis was established to determine the significant factors that best predicted the liver SUVmax. Then the subjects were dichotomised into four BMI groups. Analysis of variance (ANOVA) was established for mean difference of SUVmax of liver between those BMI groups.
RESULTS: BMI and incubation period were significantly associated with liver SUVmax. These factors were accounted for 29.6% of the liver SUVmax variance. Statistically significant differences were observed in the mean SUVmax of liver among those BMI groups (P<0.05).
CONCLUSIONS: BMI and incubation period are significant factors affecting physiological FDG uptake of liver. It would be recommended to employ different cut-off value for physiological liver SUVmax as a reference standard for different BMI of patients in PET/CT interpretation and use a standard protocol for incubation period of patient to reduce variation in physiological FDG uptake of liver in PET/CT study.

Entities:  

Keywords:  Fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT); body mass index (BMI); incubation period; liver; maximum standardized uptake value (SUVmax)

Year:  2015        PMID: 26682140      PMCID: PMC4671971          DOI: 10.3978/j.issn.2223-4292.2015.05.02

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  53 in total

Review 1.  Pitfalls in integrated CT-PET of the thorax: implications in oncologic imaging.

Authors:  Mylene T Truong; Tinsu Pan; Jeremy J Erasmus
Journal:  J Thorac Imaging       Date:  2006-05       Impact factor: 3.000

2.  [Malignant tumor with false negative 18F-FDG PET image].

Authors:  Meng-jie Dong; Xinag-tong Lin; Jun Zhao; Yi-hui Guan; Chuan-tao Zuo; Xiang Chen; Jia-zhong Dai; Bao-dong Jiang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2006-09

Review 3.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

Review 4.  Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.

Authors:  G J Cook; I Fogelman; M N Maisey
Journal:  Semin Nucl Med       Date:  1996-10       Impact factor: 4.446

5.  Dual-time-point FDG-PET/CT for the detection of hepatic metastases.

Authors:  Albert Dirisamer; Benjamin S Halpern; Wolfgang Schima; Martin Heinisch; Florian Wolf; Mohsen Beheshti; Franz Dirisamer; Michael Weber; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2008-08-16       Impact factor: 3.488

6.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

Authors:  Ronald Boellaard; Nanda C Krak; Otto S Hoekstra; Adriaan A Lammertsma
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

7.  Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h.

Authors:  Bennett B Chin; Edward D Green; Timothy G Turkington; Thomas C Hawk; R Edward Coleman
Journal:  Mol Imaging Biol       Date:  2008-11-27       Impact factor: 3.488

8.  [18F FDG PET-Applications in Oncology].

Authors:  Irena Răileanu; V Rusu; Cipriana Stefănescu; L Cinotti; D Hountis
Journal:  Rev Med Chir Soc Med Nat Iasi       Date:  2002 Jan-Mar

9.  Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis?

Authors:  Laurent Arnaud; Julien Haroche; Zoulikha Malek; Frédérique Archambaud; Laetitia Gambotti; Gilles Grimon; Aurélie Kas; Nathalie Costedoat-Chalumeau; Patrice Cacoub; Dan Toledano; Philippe Cluzel; Jean-Charles Piette; Zahir Amoura
Journal:  Arthritis Rheum       Date:  2009-04

10.  [Evaluation of various hepatic lesions with positron emission tomography].

Authors:  Hyun Bae Son; Chul Ju Han; Beung Il Kim; Jin Kim; Sook-Hyang Jeong; You Cheoul Kim; Jhin Oh Lee; Chang Yun Choi; Sang Mu Im
Journal:  Taehan Kan Hakhoe Chi       Date:  2002-12
View more
  11 in total

1.  Intrapatient repeatability of background 18F-FDG uptake on PET/CT.

Authors:  Rang Wang; Qiuping Fan; Rong Tian; Minggang Su
Journal:  Quant Imaging Med Surg       Date:  2021-09

2.  Reproducibility of [18F]FDG PET/CT liver SUV as reference or normalisation factor.

Authors:  Gerben J C Zwezerijnen; Jakoba J Eertink; Maria C Ferrández; Sanne E Wiegers; Coreline N Burggraaff; Pieternella J Lugtenburg; Martijn W Heymans; Henrica C W de Vet; Josée M Zijlstra; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-27       Impact factor: 10.057

3.  Age-related changes of standardized uptake values in the blood pool and liver: a decade-long retrospective study of the outcomes of 2,526 subjects.

Authors:  Yuan Cao; Ke Zhou; Wei Diao; Xipeng Long; Fangfang Tian; Minggang Su; Zhiyun Jia
Journal:  Quant Imaging Med Surg       Date:  2021-01

Review 4.  Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs: A systematic review.

Authors:  Clarice Sprinz; Stephan Altmayer; Matheus Zanon; Guilherme Watte; Klaus Irion; Edson Marchiori; Bruno Hochhegger
Journal:  PLoS One       Date:  2018-02-27       Impact factor: 3.240

Review 5.  Impacts of time interval on 18F-FDG uptake for PET/CT in normal organs: A systematic review.

Authors:  Rang Wang; Haotian Chen; Chengzhong Fan
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

6.  Positron emission tomography/computed tomography manifestations of primary hepatic myxoid liposarcoma: A case report.

Authors:  Weihai Liu; Wenjie Liang; Zhiyi Peng
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

7.  Radiobiological risks in terms of effective dose and organ dose from 18F-FDG whole-body PET/CT procedures.

Authors:  Suhaib Alameen; Nissren Tamam; Sami Awadain; Abdelmoneim Sulieman; Latifa Alkhaldi; Amira Ben Hmed
Journal:  Saudi J Biol Sci       Date:  2021-06-24       Impact factor: 4.219

Review 8.  FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background.

Authors:  Kumi Ozaki; Kenichi Harada; Noboru Terayama; Nobuyuki Kosaka; Hirohiko Kimura; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2020-04-03       Impact factor: 2.374

9.  Effects of blood glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an analysis on 5623 patients.

Authors:  Clarice Sprinz; Matheus Zanon; Stephan Altmayer; Guilherme Watte; Klaus Irion; Edson Marchiori; Bruno Hochhegger
Journal:  Sci Rep       Date:  2018-02-01       Impact factor: 4.379

10.  Predicting the Recurrence of Hepatocellular Carcinoma after Primary Living Donor Liver Transplantation Using Metabolic Parameters Obtained from 18F-FDG PET/CT.

Authors:  Sungmin Kang; Joo Dong Kim; Dong Lak Choi; Byungwook Choi
Journal:  J Clin Med       Date:  2022-01-12       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.